複製鏈接
請複製以下鏈接發送給好友
https://baike.baidu.hk/item/隋建華/54490510
複製
複製成功

隋建華

（北京生命科學研究所研究員）

鎖定
隋建華，女，北京生命科學研究所研究員，生物製品中心和抗體中心主任。 [1-2] 
中文名
隋建華
性    別
女

目錄

  1. 1 人物經歷
  2. 2 個人生活
  3. 3 主要成就
  4. 4 學術成果

隋建華人物經歷

1994年，蘭州大學醫學院，臨牀醫學學士。
1997年，蘭州大學醫學院，心血管內科學碩士。
2000年，中國協和醫科大學中國醫學科學院血液學研究所，病理生理學博士。
2000年–2004年，哈佛大學醫學院Dana-Farber癌症研究所博士後。
2004年–2011年，哈佛大學醫學院Dana-Farber癌症研究所講師。
2012年–，北京生命科學研究所研究員，生物製品中心主任。 [1] 
北京生命科學研究所研究員，生物製品中心和抗體中心主任 [2]  。

隋建華個人生活

丈夫：李文輝，2020年11月12日榮獲全球乙肝研究和治療領域最高獎——巴魯克·布隆伯格獎。 [2] 

隋建華主要成就

開發的第一個乙肝候選藥物為國際首創，於2019年進入臨牀試驗，目前進展順利；其餘多個相關候選創新藥物，有的正在進行臨牀前研究，有的已開始申報臨牀試驗。 [2] 

隋建華學術成果

代表性論文
1.Sui J*, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol 2014, 88 (23), 13769-80. (* co-senior author)
2.Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti-Influenza A Antibodies. Clin Infect Dis 2011; 52 (8):1003-1009 [Comment in Clin Infect Dis: Donis R, and Cox N. Prospecting the Influenza Hemagglutinin to Develop Universal Vaccines, Clin Infect Dis (Editorial commentary) 2011, 52: 1010-1012.]
3.Sui J*, Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Murakami A, Yammanuru A, Han T, Cox N, Bankston LA, Donis RO, Liddington RC and Marasco WA. Structural and Functional Basis for Broad-Spectrum Neutralization of Avian and Human Influenza A Viruses. Nat Struct Mol Bio 2009, 16(3):265-73. (*co-corresponding author) [Commented in Nat Biotech, Nat Struct Mol Bio and Nat Med: ◇ Wang TT, Palese P. Universal epitopes of inflenza virus hemagglutinins? Nat Struct Mol Biol (News and Views), 2009,16 (3):233-4. ◇ Chen, GL, Subbarao K. Attacking the flu: Neutralizing antibdoies may lead to 'universal' vaccine. Nat Med (Between Bedside and Bench), 2009, 15: 1251-1252. ◇ Influenza's Achilles' heel? Nat Biotech (Research highlights), 2009, 27 (14): 348]
4.Sui J*, Aird DR, Tamin A, Murakami A, Yan M, Yammanur, A, Jing H, Kan B, Liu, X, Zhu Q, Yuan Q, Adams GP, Bellini WJ, Xu J, Anderson LJ and Marasco WA. Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway. Plos Pathogen 2008, 4(11):e1000197.(* co-corresponding author)
5.Sui J. Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M Marasco WA. Evaluation of human mab 80r for immunoprophylaxis of SARS by an animal study, epitope mapping and analysis of spike variants. J Virol 2005, 79(10):5900-5906.
6.Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallrico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, and Marasco WA. Potent Neutralization of SARS Coronavirus Infection by a Human Monoclonal Antibody Against the ACE2-Binding Domain of Spike Protein. Proc Natl Acad Sci USA 2004,101(8):2536-41
7.Sui J, He Y, Jiang X, Dubel S, Han Z, Song Z. A single chain antibody obtained by cell panning of antibody phage inhibits homoaggregation of human leukemia cells. Hum Antibodies 2004;13(4):111-118
8.Sui J, Bai J, Tallarico A, Xu C and Marasco WA. Identification of CD4 and Transferrin Receptor Antibodies by Anti-CXCR4 Antibody Guided Pathfinder Selection. Eur J Biochem 2003; 270: 4497-4506
9.Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002, 303(1):9-14
10.He W,Ren B, Mao F, Jing Z,Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y,Guo J-T, Sui J, Wang F, and Li W. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. PLOS Pathog, 2015,10.1371/journal.ppat.1004840.
11.Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, and W. Li*. Viral entry of hepatitis B and d viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol, 2014, 88(6): 3273-84,
12.Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 2014,88:3273-3284.
13.Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G, Sui J, Li W. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013, 87:7977-7991
14.Zhong G, Yan H, Wang H, He W, Jing Z, Qi Y, Fu L, Gao Z, Huang Y, Xu G, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J Virol 2013, 87:7176-7184.
15.Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 1:e00049.
16.DK Chang, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge R, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell J, Zhu Q, Kupper T, Marasco WA. Humanization of an anti-CCR4 antibody that kills Cutaneous T Cell Lymphoma cells and abrogates suppression by T regulatory cells. Molecular Cancer Therapeutics 2012,11 (11):2451-61
17.Xu C, Sui J, Tao H, Zhu Q, Wayne A. Marasco. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-Region sulfation and define CXCR4 antigenic heterogeneity. J Immunol 2007,179(4):2408-18
18.Li W, Sui J, Huang I-Cheuh, Kuhn JH, Radoshizky S, Marasco WA, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology 2007, 367(2):367-74
19.Hannah G, Sui J, Foellmer H, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, Silva A, Koski R, Marasco WA, Fikrig E. Protection against West Nile virus with human single chain Fv-Fc fusion proteins that bind the viral envelop protein. J Virol 2005, 79:14606-4613
20.Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco WA, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in Vitro. Cancer Res 2005, 65(6):2344-2352
21.Tarnovitski N, Matthews LJ, Sui J, Gershoni JM Marasco WA. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol 2006, 359(1):190-201
22.Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005, 24: 1634-1643
23.Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-SARS Spike protein antibody, 80R. J Biol Chem 2006, 281(45):34610-6
24.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454
25.Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208(1):181-93
專利
1.Marasco WA, Sui J. Antibodies Against SARS-CoV and Methods of Use Thereof. Patent No.US7750，123
2.Marasco WA, Sui J, Xu C. Antibodies against CXCR4 and Methods of Use Thereof. Patent No. US8329178B2;EP 1871807 B1;CA 2597717 C
3.Fikrig E, Gould H, Koski RA, Ledizet M, Marasco WA, Sui J. Antibodies to West Nile Virus Polypeptides. Publication No.：WO/2005/123774. Publication date: Dec. 29, 2005.
4.Marasco WA, Sui J, Anvir Y. Humanized Monoclonal Antibodies and Methods of Use. Publication No.：WO2011153380A3. Publication date: Apr 5, 2012.
5.Marasco WA, Sui J, Liddington R. Conserved Hemagglutinin Epitopes, Antibodies To The Epitope And Methods Of Use. Publication No. US20120128684 A1. Publication date: May 24, 2012.
6.Marasco WA, Sui J, Zhu Q, Kupper T. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use. Publication No.:WO2013166500 A1. Publication date: Nov 7, 2013
7.Marasco WA, Sui J. Antibodies against H5N1 and Methods of Use Thereof. Publication No.: US20140011982 A1. Publication date: Jan 9, 2014.
8.Marasco WA, Sui J. Human monoclonal anti-PD-L1 antibodies and methods of use. (Publication No.: WO2014055897A2.). Publication date:Apr 10, 2014 [1] 
參考資料